JAGX Jaguar Health, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1585608 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY129.7%
TTM net income YoY18.7%
TTM EPS YoY199.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin81.5%
Operating margin-91.2%
Net margin-121.0%
FCF margin—
EBITDA margin-84.2%
Returns
ROE-252.4%
ROA-79.9%
ROIC (approx.)-230.8%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets42.7%
Debt / equity0.00x
Current ratio1.28x
Interest coverage-21.50x
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio-63.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.34M | $1.23M | $20.27M | $3.23M | $3.08M | $2.98M | $2.21M | $3.51M |
| Cost of revenue | $627,000 | $1.03M | $1.16M | $2.20M | $532,000 | $527,000 | $515,000 | $557,000 |
| Gross profit | $1.72M | $194,000 | $19.11M | $1.03M | $2.55M | $2.45M | $1.70M | $2.95M |
| R&D expense | $3.61M | $3.34M | $3.93M | $14.31M | $3.66M | $3.27M | $3.73M | $4.53M |
| SG&A expense | $4.08M | $4.45M | $4.11M | $4.89M | $4.13M | $4.73M | $4.90M | $3.86M |
| Operating income | -$6.02M | -$7.60M | $10.18M | -$21.24M | -$7.24M | -$8.01M | -$9.42M | -$8.16M |
| Interest expense | $156,000 | $161,000 | $699,000 | $132,000 | $6,000 | -$15,000 | -$56,000 | -$110,000 |
| Pretax income | -$5.83M | -$12.80M | $8.72M | -$23.19M | -$9.65M | -$10.56M | -$10.60M | -$10.23M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$5.71M | -$12.68M | $8.85M | -$23.20M | -$9.50M | -$10.41M | -$10.46M | -$9.92M |
| EBITDA | -$5.55M | -$7.12M | $10.65M | -$20.77M | -$6.76M | -$7.53M | -$8.94M | -$7.68M |
| EPS (basic) | -9.23 | -15.70 | -13.60 | — | -2,032.95 | -358.94 | -584.45 | — |
| EPS (diluted) | -9.23 | -15.70 | -13.60 | — | -2,032.95 | -358.94 | -584.45 | — |
| Weighted avg. shares (diluted) | 684,374 | 809,122 | 515,788 | — | 4,674 | 28,994 | 17,904 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.53M | $3.79M | $7.28M | $968,000 | $3.53M | $2.21M | $5.69M | $8.00M |
| Receivables | $554,000 | $8,000 | $68,000 | $1.52M | $1.44M | $1.17M | $1.22M | $1.53M |
| Inventory | $6.75M | $7.32M | $7.82M | $8.60M | $10.63M | $10.72M | $10.55M | $10.35M |
| Current assets | $16.39M | $17.53M | $20.21M | $20.34M | $29.40M | $27.90M | $30.44M | $32.20M |
| PP&E, net | $412,000 | $417,000 | $423,000 | $463,000 | $483,000 | $441,000 | $452,000 | $464,000 |
| Intangibles | $14.62M | $15.09M | $15.55M | $16.02M | $17.29M | $17.55M | $18.01M | $18.48M |
| Total assets | $32.51M | $34.19M | $37.43M | $38.32M | $49.47M | $48.27M | $51.46M | $53.42M |
| Current liabilities | $12.83M | $25.38M | $40.69M | $40.65M | $36.12M | $29.22M | $28.21M | $19.70M |
| Total liabilities | $13.89M | $29.27M | $53.19M | $57.01M | $45.11M | $41.39M | $48.15M | $44.45M |
| Shareholders' equity | $20.32M | $6.62M | -$14.18M | -$17.29M | $5.63M | $7.99M | $1.78M | $7.29M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.93M | -$5.34M | $8.83M | -$5.49M | -$4.69M | -$6.19M | -$7.31M | -$7.83M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$7.83M |
| Investing cash flow | — | — | — | $13,000 | — | — | — | -$215,000 |
| Financing cash flow | $3.85M | $1.86M | -$6.62M | $9.79M | $6.26M | $2.65M | $4.97M | $2.83M |
| Depreciation & amortization | $473,000 | $473,000 | $473,000 | $477,000 | $479,000 | $478,000 | $479,000 | $478,000 |
| Stock-based compensation | $168,000 | $171,000 | $155,000 | $116,000 | $135,000 | $279,000 | $301,000 | $372,000 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.